J. Vilar-Alejo

发表

Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2012, Archives of dermatology.

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

J. Carrascosa, I. Belinchón, G. Carretero, 2018, The Journal of dermatological treatment.

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

M. Llamas-Velasco, R. Botella-Estrada, I. García-Doval, 2020 .

Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

M. Llamas-Velasco, R. Botella-Estrada, I. García-Doval, 2020, Acta dermato-venereologica.

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

M. Llamas-Velasco, I. García-Doval, J. Carrascosa, 2021, The Journal of dermatological treatment.

SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.

J. Vilar-Alejo, L. Dehesa, J. Bastida, 2010, Acta dermato-venereologica.

[Surgical treatment of relapsing keloid of the pinna by fillet flap].

J. Vilar-Alejo, J. Domínguez-Silva, G. Carretero‐Hernández, 2010, Actas dermo-sifiliograficas.

Migratory, recurrent skin eruption in a returning traveller

J. Vilar-Alejo, J. Pérez-Arellano, M. Grau-Pérez, 2018, The Australasian journal of dermatology.

[Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].

G. Carretero, J. Vilar-Alejo, L. Dehesa, 2009, Actas dermo-sifiliograficas.

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020 .

Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the spanish biobadaderm registry.

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020, Actas dermo-sifiliograficas.

Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020, Journal of the American Academy of Dermatology.

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

I. Belinchón, G. Carretero, J. Sánchez-Carazo, 2018, The Journal of dermatological treatment.

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

M. Llamas-Velasco, R. Botella-Estrada, I. García-Doval, 2020, Journal of the American Academy of Dermatology.